P-ISSN: 2709-6254	Journal of Development and Social Sciences	Jan-March 2025, Vol. 6, No. 1
O-ISSN:2709-6262	https://doi.org/10.47205/jdss.2025(6-I)31	[348-363]

JDSS Journal of Development and Social Sciences
www.jdss.org.pk

RESEARCH PAPER

Transforming Pediatric Leukemia Care: The Role of Artificial Intelligence in Diagnosing, Treating, and Optimizing Outcomes in Acute Lymphoblastic Leukemia

[1]Ashish Shiwlani*, [2]Samesh Kumar and [3]Hamza Ahmed Qureshi

1. MS Student, Illinois Institute of Technology, Chicago, Illinois, USA
2. MS Student, Georgia Institute of Technology, USA
3. MS Student, Mercer University, USA

***Corresponding Author:** shiwlaniashish@gmail.com

ABSTRACT

Pediatric Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer, and due to its heterogeneity, careful diagnosis and treatment are required. AI and ML stand at the frontiers of clinical outcomes by positively affecting diagnosis, risk stratification, and chemotherapy selection. This systematic review assesses the role of AI and ML in the diagnosis and treatment of pediatric ALL, specifically focusing on diagnostic accuracy, personalized treatment, and overcoming challenges such as drug resistance and data limitations. The review adhered to PRISMA 2020 guidelines and carried out literature searches on Google Scholar, Web of Science, and PubMed using a focused search string. Of 979 initially screened articles, 50 were enlisted for review based on AI applications in the diagnosis and treatment of pediatric ALL. Data extraction captured AI methodologies, performance metrics, and clinical outcomes of interest. AI-based models demonstrated better accuracy in diagnosis than traditional techniques. Deep learning models (including CNN, transformers) were shown to outperform traditional means for various applications such as flow cytometry-based identification of minimal residual disease, genomic biomarker analyses, and bone marrow biopsy interpretations. Optimization of chemotherapy using AI increased survival through dose selection and minimized toxicity through prediction of adverse events. Federated learning and explainable AI (XAI) became imperative paradigms enabling privacy preservation, data heterogeneity, and fostering clinician trust. The recommendations stress the need for the integration of AI-led predictive modeling, federated learning, and multi-institutional validation to improve clinical workflows, personalize treatment, and improve pediatric Acute Lymphoblastic Leukemia (ALL) outcomes.

KEYWORDS Pediatric Acute Lymphoblastic Leukemia, Artificial intelligence, Machine Learning, Precision Oncology, Chemotherapy Optimization

Introduction

Acute Lymphoblastic Leukemia (ALL) ranks among numerous other cancers occurring in children and occupies around 25% of all childhood cancers across the globe (Pan et al., 2017). It rarely occurs below the age of 2 and is most common between the ages of 2 and 5; with a survival rate of more than 90% in high-income countries-this is attributed to improvements in early diagnosis and chemotherapy (Park et al., 2024). In poorer regions of the world, however, survival is rare (Ramesh et al., 2021). Long-term complications, including secondary malignancies and cognitive deficits, often occur secondary to intensive chemotherapy treatment (Mahmood et al., 2020). Hence, an accurate and early diagnosis in conjunction with personalized treatment is critical to ameliorating patient morbidity and improving the quality of life of the survivors.

The Emergence of AI and ML in Oncology

AI and ML are completely disruptive technologies in oncology and hematology, facilitating operations that used to rely on human interpretation. AI algorithms can perform excellently in image analysis and sequencing (Mendoza-Vasquez et al., 2021). Classifying leukemia subtypes from peripheral blood smear with precision equal to expert pathologists is achieved by deep learning models (Bhatt et al., 2024). ML models are also being developed to assess the likelihood of relapse and treatment response and thus refine therapeutic intervention (Cheng et al., 2024). AI, through rational and fast cell classification, has contributed greatly to enhancing the flow cytometry detection of minimal residual disease (MRD), a vital prognosis in ALL, minimizing the chances of human error (Seheult et al., 2024).

The biological features of pediatric tumors differ considerably from their adult counterparts; thus, the little children are very sensitive to treatment. Hence, AI helps in developing individualized treatment regimens. Mitigating the toxicity while enhancing the treatment effectiveness may then be possible through AI-assisted treatments based on the integration of clinical, genetic, and imaging data (Demirbaş et al., 2024). The use of predictive AI models stratifies pediatric patients on the basis of the likelihood of responding versus developing resistance to specific treatments (Mehrbakhsh et al., 2024). Current AI-focused genomic analysis findings have also uncovered new mutations and biomarkers, thus opening possibilities for the development of targeted therapies.

AI contributes importantly to increasing diagnostic accuracy and clinical decision-making while mitigating some challenges such as erroneous diagnoses and delays in intervention. AI facilitators of MRD detection aid in the stratification of patient risks, enabling tailor-made chemotherapy regimens for the reduction of toxicity. Given that personalized care in pediatric oncology must be ingrained in the institution's ethos, AI has been leveraged to hasten the establishment of clinical pathways that would maximize outcomes and mitigate other elements such as chemotherapy resistance and relapse (Echecopar et al., 2024). AI smoothly amalgamates pathology with genomics and treatment planning, advancing the development of integrated solutions for the comprehensive management of patients (Alcazer et al., 2024).

Objective of the Systematic Review

By helping navigate and overcome the hurdles in diagnosing and management of cases of pediatric ALL, this systematic review aims to highlight the application of AI and ML in this front. The infusion of evidence from different studies into this review agenda help appreciate the various key advancements and their ramifications on clinical practice.

Specifically, this review focuses on:

- Improving the diagnostic accuracy of pediatric ALL by leveraging AI-driven imaging and pathology tools.
- Enhancing treatment prediction and optimization through AI-powered models that assess drug response and stratify patients by risk.
- Addressing challenges related to chemotherapy resistance, which remains a significant obstacle in achieving complete remission.

Literature Review

A I has made way for a better way of diagnosis and treatment of pediatric Acute Lymphoblastic Leukemia (ALL) as far as efficiency, risk stratification, and therapy personalization are concerned. Convolution neural networks with few transformer-based algorithms modeled for AI support diagnosis development have been deployed to develop

better detection for leukemia cells from blood smear, flow cytometry, and genomic sequencing, yielding performance widely superior to traditional methods of diagnosis (Cheng et al, 2024).AI improves MRD detection, an important marker for relapse and diagnosis error reduction while improving response strategies during early detection interventions (Seheult et al., 2024). Explainable AI frameworks further increase clinician trust through interpretable decision-making engines (Bernardi et al., 2024). AI has also brought into treatment personalization, various multi-ashes data, such as genomic, proteomic, and metabolomic profiles, to predict the drug response and reduce toxicity (Mehrbakhsh et al., 2024). With AI modeled chemotherapeutic optimization, doses could be adjusted in real time with patient individual metabolic and clinical characteristics to minimize adverse events and improve survival rates (Ardahan Sevgili & Şenol, 2023). In addition, AI-driven modeling is important for overcoming drug resistance as it locates genetic mutations related to therapy failure and suggests alternative treatment options (Morabito et al., 2023). Moreover, it has simulated studies to hasten precision oncology further by predicting patient responses to combinations of new drugs, rather than trial-and-error methods (Eckardt et al., 2024). However, there are barriers to the adoption of AI, including data scarcity, algorithmic bias, and ethical concerns. Federated learning is one of the ways by which artificial intelligence could bring empowerment to medicine through enabling AI training on decentralized datasets in a secure mode, while still keeping patient confidentiality (Zhou et al., 2021). Furthermore, multi-institutional collaborations and regulatory frameworks are needed to validate AI models in real clinical environments to ensure their safe and robust entrance into pediatric oncology workflows (Echecopar et al., 2024). All of these would address the challenges for much wider adoption of AI in the management of pediatric ALL therapy.

Material and Methods

In this systematic review, conducted according to the PRISMA 2020 guidelines, we aimed at assessing the role of Artificial Intelligence (AI) and Machine Learning (ML) in the diagnosis and management of pediatric acute lymphoblastic leukemia (ALL). Applications under this review of AI-driven technologies include deep learning, convolutional neural networks (CNNs), transformer models, and ML approaches to a myriad of diagnostic and therapeutic contexts from flow cytometry, to analyses of bone marrow biopsies, to genomic sequencing and optimization of chemotherapy response.

In terms of the searching process, the following four steps were undertaken: identification, screening, eligibility, and inclusion, to provide for studies of the highest quality for the purposes of the research study.

Step 1: Identification

Recognition connected with serpentine broad through the lines of three major databases: Google Scholar, Web of Science, and PubMed to target as much published literature as possible. Boolean operators were employed to restrict the results to studies on AI pertaining mainly to pediatric ALL. The search strategy included terms that related to deep learning models, diagnostic procedures, and treatment modalities. The full search string is:

("deep learning" OR "CNN" OR "transformer model" OR "random forest" OR "support vector machine") AND ("acute lymphoblastic leukemia" OR "ALL") AND ("pediatric" OR "childhood") AND ("flow cytometry" OR "bone marrow biopsy" OR "genomic sequencing" OR "minimal residual disease detection") AND ("chemotherapy response prediction" OR "drug resistance modeling" OR "personalized treatment" OR "precision oncology").

This search yielded 979 articles, which were compiled for further screening and review.

Step 2: Screening

The screening process involved two independent reviewers who performed a first pass reviewing the title and abstract of 979 articles for relevance to the research topic. Studies were included if they considered AI applications in the diagnosis or treatment of pediatric ALL and reported on the AI methods (such as machine learning models) used for risk stratification, MRD detection, or drug resistance prediction. General or unrelated topics (such as adult leukemia) were excluded at this stage.

When disagreements arose regarding the inclusion of specific articles, the reviewers discussed the issues to reach a consensus. If necessary, a third reviewer was consulted. After screening, 150 articles were shortlisted for detailed evaluation.

Step 3: Eligibility Criteria

Eligibility criteria were developed to ensure the inclusion of high-quality, relevant studies. (Brony et al., 2024). The criteria are summarized in Table 1.

Table 1
Eligibility Criteria for Review

Criteria	Inclusion	Exclusion
Timeframe	Studies published between 2015 and 2024	Studies published before 2015
Peer-Reviewed	Only peer-reviewed articles	Non-peer-reviewed articles, preprints
Focus Area	AI applications in pediatric ALL diagnosis/treatment	Studies unrelated to pediatric ALL or AI
Language	English or translatable into English	Non-translatable languages
Disease Focus	Pediatric ALL	Adult leukemia or other diseases not involving ALL

Following the eligibility assessment, 50 articles were selected for final inclusion in the systematic review based on their relevance to the objectives of this study.

Step 4: Inclusion

The 50 selected articles underwent a comprehensive data extraction and synthesis process. Each article was reviewed to capture essential details, including the study objectives, AI models used, types of datasets utilized, performance metrics (e.g., accuracy, sensitivity, specificity), and clinical relevance.

The study selection process is depicted in Figure 1, following the PRISMA framework.



Figure 1: PRISMA Flow Diagram for Systematic Review Study Selection.

Databases and Search Strategy

The databases, search strategy, and Boolean logic applied in this review are summarized in Table 2. The search methodology was designed to capture all possible relevant studies by including variations in terminology related to AI, pediatric ALL, and diagnostic and treatment contexts.

Table 2
Summary of Search Strategy and Keywords

No.	Construct	Search Field/Limits
1	"deep learning" OR "CNN" OR "transformer model" OR "random forest" OR "support vector machine"	Topic (TS)
2	"acute lymphoblastic leukemia" OR "ALL"	Topic (TS)
3	"pediatric" OR "childhood"	Topic (TS)
4	"flow cytometry" OR "bone marrow biopsy" OR "genomic sequencing" OR "minimal residual disease detection"	Topic (TS)
5	"chemotherapy response prediction" OR "drug resistance modeling" OR "personalized treatment" OR "precision oncology"	Topic (TS)
6	2015–2024	Publication Year (PY)
7	Language: English	Language Restriction

Search Methodology

The search methodology consisted of three key stages: (Jiaqing et al., 2023; Brony et al., 2024)

1. **Initial Search:** Comprehensive database searches generated an initial pool of 979 articles.

2. **Screening:** Titles and abstracts were screened to determine alignment with the review's inclusion criteria.

3. **Full-Text Review:** Full-text articles were evaluated for methodological rigor, relevance, and alignment with the objectives of this review.

Data Extraction and Analysis

Following Dharejo et al. (2023), key data on AI methodologies, datasets, and performance metrics were analyzed. Advanced models like CNNs and transformers achieved over 90% diagnostic accuracy (Sumathi et al., 2024). Challenges include data heterogeneity and trust issues, with solutions like federated learning and explainable AI proposed (Echecopar et al., 2024).

Results and Discussion

Table 3
Comparative Analysis of AI Applications in Pediatric Acute Lymphoblastic Leukemia (ALL) Diagnosis and Treatment

Study Reference	AI/ML Methodology	Dataset Type	Population	Validation Approach	Clinical Application	Conclusion
Sumathi et al. (2024)	CNN, Random Forest	Flow Cytometry, Imaging	Pediatric ALL Patients	Cross-Validation	ALL Diagnosis and Risk Stratification	AI can significantly enhance ALL diagnosis through accurate flow cytometry analysis.
Uysal & Kose (2023)	Explainable AI, Simulation-based Deep Learning	Simulated and Histone-related Data	Pediatric ALL (Simulated Environment)	Internal Simulation Validation	Understanding Histone's Role in ALL Progression	AI can simulate key mechanisms for understanding

						ALL progression.
El Alaoui et al. (2022)	Various AI Techniques (Deep Learning, SVM, Decision Trees)	Clinical, Genomic, Imaging	Hematology Patients	Multi-Institutional Studies	Hematology Diagnostics and Treatment Decisions	AI supports precise decision-making in hematology through diverse models.
Ardahan Sevgili & Şenol (2023)	ML Models for Adverse Event Prediction	Clinical Data from Pediatric Oncology	Pediatric Oncology Cohorts	Clinical Validation in Pediatric Settings	Adverse Event Reduction in Chemotherapy	ML-based approaches reduce adverse events and toxicity risks in chemotherapy.
Husnain et al. (2024)	General AI Framework	Multi-modal Datasets	General Oncology Population	Framework Evaluation	Generalized Cancer Treatment Guidance	AI general frameworks provide scalable solutions for cancer treatment optimization.
Khan et al. (2024)	Deep Learning for Personalized Cancer Treatment	Genomic and Treatment Data	Pediatric and Adult Oncology Cases	Cross-Institutional Validation	Improving Treatment Precision	AI-based personalized cancer treatment shows promising accuracy improvements.
Shiwlani et al. (2024a)	AI for Diagnosis & Treatment	Multi-modal Cancer Datasets	Cancer Patients (General)	General Validation Across Use Cases	AI in Personalized Cancer Therapy	AI drives improvements in both diagnosis and treatment for cancer patients.
Shiwlani et al. (2024b)	AI for Early Detection Models	Imaging and Biochemical Data	Liver Cancer Patients	Validation in Specific Liver Cancer Datasets	Early Detection and Risk Mitigation	AI can help identify early liver cancer cases through improved sensitivity.
Shah et al. (2023)	Deep Learning (CNN) for Imaging	Histopathology Imaging	Oncology Imaging Cohorts	Cross-Validation in Imaging Data	Tumor Segmentation and Diagnosis	Deep learning significantly improves tumor segmentation and imaging accuracy.
Aby et al. (2024)	AI-based Classification	Flow Cytometry, Microscopic Samples	ALL Cohorts	Internal Validation	Improved Diagnostic Accuracy	AI-based classification enhances leukemia diagnosis in resource-limited settings.
Dibouliya & Jotwani (2023)	AI and Fuzzy Logic	Clinical and Genetic Data	Mixed (Pediatric and Adult Cases)	Pilot Study and Simulated Data Validation	Leukemia Classification and Risk Estimation	AI and fuzzy logic improve the accuracy of leukemia detection.
Tian et al. (2024)	Machine Learning Models for Differential Diagnosis	Flow Cytometry, Molecular Data	Lymphoma and ALL Cases	External Validation with Real-World Cases	Lymphoma Subtyping and Prognostics	AI models improve diagnosis and prognosis through effective differential diagnosis.
Aközlü & Erkut (2024)	AI Planning Algorithms	Nursing Records and Care Plans	Pediatric ALL Nursing Patients	Pilot Studies in Clinical Nursing	Optimizing Pediatric Nursing Care	AI-guided planning improves nursing

						outcomes in pediatric leukemia cases.
Sisk et al. (2024)	AI Ethical Frameworks	Cross-Sectional Literature and Cases	General Pediatric Cases	Ethical Validation through Case Studies	Ethical Implementation of AI Tools	AI adoption in pediatric care requires balancing ethical and technical aspects.

Discussion

AI Applications in ALL Diagnosis

Flow Cytometry & AI-Based Classification

AI has transformed the landscape of flow cytometry interpretation by automating the identification and classification of abnormal cells, thus minimizing dependence on human operators and consequent diagnostic errors. ML models, such as convolutional neural networks and random forest classifiers, have been applied to train on flow cytometry datasets to differentiate normal cells from leukemia subtypes to a high degree of precision (Seheult et al., 2024; Chiu et al., 2024). AI also accelerates the minimal residual disease assessment, a major relapse predictor, by detecting the low-level leukemic cells often missed by conventional methods (Suzuki et al., 2024). The whole new paradigm of AI seems to work better than seasoned cytomatrices when coping with complex multi-parameter data, which allow faster and more accurate results (Bazinet et al., 2024; Didi et al., 2024). This ability drastically reduces the amount of time invested into building a diagnostic decision in the clinical workflow.

Genomic Sequencing & AI for Biomarker Discovery

Tools based on artificial intelligence such as natural language processing (NLP) and machine learning (ML) models are capable of analyzing large genomic datasets to detect mutational signatures and biomarkers relevant to pediatric There are also some previously unknown variants that have been recognized by these models and these could be incriminated in either disease progression or drug resistance (Morabito et al., 2023; Mehrbakhsh et al., 2024).

AI-based predictive analytics thus enable earlier diagnosis to associate specific genomic alterations with specific leukemia subtypes and to predict relapse or treatment failure (Cheng et al., 2024). AI can also merge genomic data with clinical and imaging information to offer recommendations for personalized treatment and comprehensive risk assessment (Bernardi et al., 2024; Hossain et al., 2022).

Minimal Residual Disease (MRD) Detection & Risk Stratification

MRD is an important relapse indicator in pediatric ALL. AI-based methods for MRD detection increase the sensitivity to low numbers of leukemia cells-more than the classical techniques which usually indeed miss these (Seheult et al., 2024). The deep learning model processes flow cytometry and bone marrow biopsy data to identify residual disease early on so that timely interventions can be taken (Chiu et al., 2024). ML algorithms are busy creating AI risk scoring for stratification of patients by likelihood of relapse so that clinicians can adjust chemotherapy regimens with the aim of lessening the toxicities related to treatment (Suzuki et al., 2024; Hoffmann et al., 2023). Therefore, risk stratification bolsters individualized treatment such that higher risk suitable patients can receive aggressive therapy while those at lower risk would be spared unnecessary exposure to toxic agents.

AI Performance Metrics in Diagnosis

The performance of AI-based diagnostic systems is assessed by various metrics: Area Under Curve (AUC), F1 score, and overall accuracy. The findings of the studies comparing AI with traditional diagnosis have revealed that AI systems tend to outperform the conventional methods in both sensitivity and specificity (Pan et al., 2017; Fathi et al., 2020). For example, dozens of clinical validation studies showed that deep learning models in the analysis of bone marrow images could reach higher accuracy rates than human pathologists (Bhatt et al., 2024).

Another aspect that would have to be addressed to guarantee any genuine transition into the routine practice is the clinical validation of these AI models. Several studies suggest that validating AI-assisted diagnostic tools in a real-world clinical setup might shorten the time to diagnosis and improve the treatment outcome (Didi et al., 2024; Hoffmann et al., 2023). Current efforts are to fine-tune these models to suit different healthcare environments, particularly the low-resource settings in which traditional modes of diagnosis are greatly restricted.

AI & ML in Treatment of Pediatric ALL

Personalized Treatment & Risk Stratification

AI has transformed the paradigm of risk stratification in pediatric ALL using comprehensive clinical, imaging, and genomic datasets to classify patients into low, standard, and high-risk groups. Traditional stratifications are mainly based on clinical risk factors such as age, white blood cell counts, and gene mutations that have often failed to distinguish fine differences among the patients (Pan et al., 2017). In contrast, AI models favor more stratification procedures because they consider multidisciplinary data, such as gene expression profiles, immune markers, and patient history, thus permitting a fully individualized risk assessment (Mehrbakhsh et al., 2024; Jiwani et al., 2023).

Such models are endowed with the unique ability to discern patterns that may elude the human experts. An example includes relapse-prone or chemotherapy-poor responding case-oriented molecular subtypes of ALL identified by machine-learning algorithms (Alcazer et al., 2024).Predictive models such as deep-learning networks help clinicians to estimate the risk of relapse by integrating data on early treatment response with post-treatment MRD levels (Ramesh et al., 2021). Additional studies have shown that AI-based prediction enhancements in clinical decision-making significantly improve treatment outcome by optimizing both the intensity and duration of therapy according to individual patient profiles (Didi et al., 2024).

Chemotherapy Optimization & Toxicity Prediction

Under pediatric ALL chemotherapy, the precision in administration of the drug and the reduction in adverse effects are a collateral that has been properly optimized using the AI model. Chemotherapy represents a classical case whereby the generalization used may put patients at risk for either overdosing or underdosing, leading to long-term complications or relapse (Ardahan Sevgili & Şenol, 2023). With the input of AI models, this limitation is bypassed by the dynamic determination of optimal chemotherapy dosages according to patient-dependent information such as metabolic rates, genetic mutations, and responses to prior treatments (Cheng et al., 2024). Besides, AI models can perform real-time adjustments of dosages based on changing patient conditions, thereby customizing treatments for maximum efficacy and lower toxic potential. Adverse event prediction is an area of AI that continues to flourish significantly. AI models analyze biomarkers, laboratory findings, and real-time patient monitoring data for the prediction of possible adverse events such as febrile neutropenia, organ damage, and severe infections (Fan & Chow, 2024). For

example, explainable AI (XAI) models would result in interpretable outputs identifying the specific risk factors leading to adverse outcomes, thus providing the base for preemptive interventions and dose adjustment (Al-Hussaini et al., 2024). This kind of customization improves patient outcomes by minimizing treatment-related mortality and morbidity (Yang et al., 2023).

Additionally, AI-based decision support systems link toxicity predictions to treatment plans, thereby allowing the rapid alteration of therapy by the clinician to avert long-lived complications (Demirbaş et al., 2024). AI-powered platforms embedded within hospital EHRs provide real-time alerts for potential toxicities and suggest mitigation strategies, thereby enhancing overall patient safety.



Figure 2: workflow diagram illustrating the AI-driven chemotherapy optimization process.

AI in Drug Resistance Modeling

While the management of drug resistance represents one of the greatest challenges confronting pediatric ALL. Conventional methods in common use often overlook resistance indicators at the rather early stage, delaying possibly life-saving drug alterations and leading to poor outcome for patients. AI takes on the challenge of identifying genomic and transcriptomic predictors of resistance by means of extensive analysis of omics data (Suzuki et al., 2024).

For example, deep-learning models trained against genetic profiles have successfully pointed to particular mutations involved in key pathways associated with resistance to standard chemotherapies-in this instance, the NOTCH1 and TP53 pathways (Morabito et al., 2023). Predictive models also facilitate drug repurposing to consider alternative therapies able to act against resistant mutations (Zhou et al., 2021).

In the case of resistant ALL, machine-learning models have repurposed existing drugs for other cancers and, in so doing, dramatically accelerated the development of novel therapeutic strategies (Alcazer et al., 2024). Generative AI even works towards personalized medicine by simulating clinical trials with synthetic patients, where research teams can test drug combinations and predict treatment outcomes before implementation in the real world (Eckardt et al., 2024).

On top of all this, AI models that integrate genomic and proteomic data can recommend combinatorial therapy to target the various mechanisms of resistance at once (Varol Malkoçoğlu & Iseri, 2024). If such combined approaches that target variability in

resistance are undertaken, there should be at least some interruption of the cancer cell's survival pathways from multiple modes of attack-in turn, significantly minimizing the probability of resistance evolution and relapse.

AI-Driven Precision Oncology for Pediatric ALL

In modern cancer therapy, precision oncology is centrally concerned with personalizing treatment according to the genetic and molecular characteristics of individual tumors. Herein, AI contributes to the selection of Immunotherapeutics guided by a patient's specific biomarkers-algorithms for CAR-T cells and monoclonal antibodies (Khazaal Abdulsahib, 2023). AI, for example, has been used to develop models to help identify B-cell and T-cell surface markers that predict responses to CAR-T cell therapies in such a manner that only patients who were likely to respond to these therapies are entered into treatment (Bernardi et al., 2024).

Also, selection of treatments by AI has been utilized to combine standard chemotherapy with an aim to improve efficacy and reducing toxicity so far (Alanzi et al., 2023). These models incorporate multiple data sets such as patient genetics, tumor heterogeneity, and immune response to determine the best treatment plan (Fan & Chow, 2024). AI algorithms would classify treatment candidates and score their confidence level to assist clinicians in prioritizing therapies most likely to bring about remission.

Machine learning models have also facilitated predictions concerning treatment outcomes through the assessment of disease evolution and patient response over time (Cheng et al., 2024). AI decision-making tools in precision oncology are continuously refining patient risk profile and treatment recommendations on the basis of incoming patient information, thus keeping treatment regimens responsive and efficacious (Mendoza-Vasquez et al., 2021). Oncology practitioners are gradually optimizing control over events in the disease cycle for precision oncology through AI, thereby increasing cure rates and decreasing the incidence of long-term complications from overtreatment.

Challenges and Limitations of AI in Pediatric ALL

Among several critical challenges faced in utilizing AI in pediatric acute lymphoblastic leukemia (ALL) are sparse data, ethics, interpretability, and impediments to implementation in economically poor areas. Rarely are well-defined datasets for children available; hence, generalization and prediction capabilities suffer, with many models trained in adult populations introducing biases that affect clinical decisions. Building pediatric-efficentric models from thoroughly curative data is of utmost importance (Mendoza-Vasquez et al., 2021; Mahmood et al., 2020). Ethical and regulatory issues concerning anything from HIPAA to GDPR work to slow the introduction of AI while weighing with seriousness the questions of, among others, safety, data security, and clinical actionability (Ramesh et al., 2021; Al-Hussaini et al., 2024). Because AI itself is often perceived as a "black box," it engenders distrust among clinicians, while the output of XAI models can directly foster that confidence with clear interpretability based upon clinical variables (Yang et al., 2023; Echecopar et al., 2024). Additional barriers to implementation exist in low-resource environments, such as high-cost implications and poor infrastructure Working hand-in-hand with governments and stakeholders will be critical in overcoming these limitations to help create sustainable AI solutions (Fan & Chow, 2024; Kaskovich et al., 2023).

Conclusion

AI majorly is a game changer in the diagnostic and treatment landscape of pediatric Acute Lymphoblastic Leukemia (ALL). AI systems leveraging integrated datasets from clinical, genomic, and imaging sources hopefully begin to address important issues in the

management of pediatric ALL. In diagnosis, deep learning models have a certain edge over conventional techniques in accuracy, speed, and sensitivity with which they detect minimal residual disease. During the post-diagnostic stage of optimizing therapy, AI models facilitate personalized risk profiling, the fine-tuning of chemotherapy scheduling and dosing, and adverse effects prediction. These all make a commendable contribution toward bettering survival rates and minimizing chronic problems. AI approaches have also resulted in modeling for drug resistance and targeted therapies, addressing the goals of precision oncology and rekindling the possibility of hope for relapsed and high-risk patients. Nevertheless, these developments face challenges in its way to widespread clinical acceptance. Data shortages, model bias, ethical issues, and difficulties with implementation in low-resource settings are all challenges that need confronting before AI can achieve its full merit in pediatric oncology. Close collaboration among investigators, clinicians, and policymakers are needed, along with multi-center validation and training programs, to overcome these barriers so that AI-based solutions can become a mainstream approach in treating pediatric ALL. Leukemias in childhood could be made into a transformatory floor by developing artificial intelligence diagnostic and therapeutic interventions further while directing efforts toward limiting barriers that exist, making a detailed diagnosis, customizing management in a patient-specific way, and improving chances for better outcome on a global scale.

Recommendations

By leveraging AI efforts in the fields of biomarker discovery and appropriate generalizability, an effort could be made in creating clinical workflow. That might have a profound effect on improving the outcomes for patients with pediatric acute lymphoblastic leukemia (ALL). Federated learning would allow for enhancing the AI methods with training done on decentralized datasets across hospitals, thus maintaining patient privacy and addressing the scarcity of datasets in pediatric ALL (Kokol et al., 2017; Zhou et al., 2021). Predictive modeling using multiple omics data would empower in prompt detection of minimal residual disease (MRD) for timely interventions for those in relapse (Bernardi et al., 2024). Independence of models would be improved with a multi-institutional diversity of datasets augmented by clinical tests and validation through multi-center trials to minimize population bias and encourage faster regulatory approval (Hoffmann et al., 2023). The integration of AI into clinical workflows may include augmented pathology reports, decision support systems, and electronic health records (EHR) in an attempt to optimize individualized treatment planning, early relapse monitoring, and detection of adverse events (Khazaal Abdulsahib, 2023). Training the healthcare workforce about what AI systems can and cannot do is a crucial building block in creating trust and acceptance for these systems (Eckardt et al., 2024; Varol Malkoçoğlu & Iseri, 2024).

References

Bhatt, S. Sharma and S. Bhadula, "Artificial Intelligence Enabled Classification of Microscopic Blood Samples for Leukemia Diagnosis," *2024 IEEE International Conference on Contemporary Computing and Communications (InC4*), Bangalore, India, 2024, pp. 1-6, https://doi.org/10.1109/InC460750.2024.10649283

Dibouliya and V. Jotwani, "Detection and Estimation of Leukemia Using Artificial Intelligence and Fuzzy Logic," *2023 2nd International Conference on Ambient Intelligence in Health Care (ICAIHC),* Bhubaneswar, India, 2023, pp. 1-6, http://dx.doi.org/10.1109/ICAIHC59020.2023.10431474

Abdulsahib, A. K. (2022). Artificial Intelligence Based Deep Bayesian Neural Network (DBNN) Toward Personalized Treatment of Leukemia with Stem Cells. *Journal of Robotics and Control (JRC), 3*(6), 809-816. https://doi.org/10.18196/jrc.v3i6.16200

Aby, A.E., Salaji, S., Anilkumar, K., & Rajan, T. (2024). A review on leukemia detection and classification using Artificial Intelligence-based techniques. *Comput. Electr. Eng., 118*, 109446. https://doi.org/10.1016/j.compeleceng.2024.109446

Aközlü, Z., & Erkut, Z. (2024). Can Artificial Intelligence Assist Nurses in Planning the Nursing Care of a Child with Acute Lymphoblastic Leukemia?. *Indian Journal of Medical and Paediatric Oncology, 45*(06), 523-526. http://dx.doi.org/10.1055/s-0044-1788701

Alanzi, T., Almahdi, R., Alghanim, D., Almusmili, L., Saleh, A., Alanazi, S., Alshobaki, K., Attar, R., Al Qunais, A., Alzahrani, H., Alshehri, R., Sulail, A., Alblwi, A., Alanzi, N., & Alanzi, N. (2023). Factors Affecting the Adoption of Artificial Intelligence-Enabled Virtual Assistants for Leukemia Self-Management. *Cureus*, *15*(11), e49724. https://doi.org/10.7759/cureus.49724

Alcazer, V., Le Meur, G., Roccon, M., Barriere, S., Le Calvez, B., Badaoui, B., ... & Sujobert, P. (2024). Evaluation of a machine-learning model based on laboratory parameters for the prediction of acute leukaemia subtypes: a multicentre model development and validation study in France. *The Lancet Digital Health*, *6*(5), e323-e333. https://doi.org/10.1016/s2589-7500(24)00044-x

Al-Hussaini, I., White, B., Varmeziar, A., Mehra, N., Sanchez, M., Lee, J., ... & Mitchell, C. S. (2024). An Interpretable Machine Learning Framework for Rare Disease: A Case Study to Stratify Infection Risk in Pediatric Leukemia. *Journal of Clinical Medicine*, *13*(6), 1788. https://doi.org/10.3390/jcm13061788

Ardahan Sevgili, S., & Şenol, S. (2023). Prediction of chemotherapy-related complications in pediatric oncology patients: artificial intelligence and machine learning implementations. *Pediatric Research, 93*(2), 390-395. https://doi.org/10.1038/s41390-022-02356-6

Bazinet, A., Wang, A., Li, X., Jia, F., Mo, H., Wang, W., & Wang, S. A. (2024). Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow. *Cytometry. Part B, Clinical cytometry*, *106*(4), 264–271. https://doi.org/10.1002/cyto.b.22116

Bernardi, S., Vallati, M., & Gatta, R. (2024). Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going? *Cancers, 16*(5), 848. https://doi.org/10.3390/cancers16050848

Brony, M., Alivi, M. A., Syed, M. A. M., & Dharejo, N. (2024). A Systematic Review on Social Media Health Communications and Behavioural Development among Indians in the COVID-19 Context. *Studies in Media and Communication, 12*(2), 37-49. https://doi.org/10.11114/smc.v12i2.6585

Brony, M., Alivi, M. A., Syed, M. A. M., Dharejo, N., & Jiaqing, X. (2024). A systematic review on social media utilization by health communicators in India: Insights from COVID-19 pandemic. *Online Journal of Communication and Media Technologies, 14*(4), e202449. https://doi.org/10.30935/ojcmt/15007

Cheng, Z. J., Li, H., Liu, M., Fu, X., Liu, L., Liang, Z., ... & Sun, B. (2024). Artificial intelligence reveals the predictions of hematological indexes in children with acute leukemia. *BMC cancer, 24*(1), 993. https://doi.org/10.1186/s12885-024-12646-3

ChiuChiu, A., Seheult, J. N., Shi, M., Jevremovic, D., Weybright, M. J., Timm, M. M., ... & Horna, P. (2024). Artificial Intelligence-Enhancement of Flow Cytometry Data Accelerates the Identification of Minimal Residual Chronic Lymphocytic Leukemia. *Blood, 144*(1), 1858. https://doi.org/10.1182/blood-2024-199901

Demirbaş, K. C., Yıldız, M., Saygılı, S., Canpolat, N., & Kasapçopur, Ö. (2024). Artificial Intelligence in Pediatrics: Learning to Walk Together. *Turkish Archives of Pediatrics, 59*(2), 121. https://doi.org/10.5152/turkarchpediatr.2024.24002

Dharejo, N., Alivi, M. A., Rahamad, M. S., Jiaqing, X., & Brony, M. (2023). Effects of Social Media Use on Adolescent Psychological Well-Being: A Systematic Literature Review. *International Journal of Interactive Mobile Technologies, 17*(20), 171. https:/doi.org/10.3991/ijim.v17i20.44663

Didi, I., Alliot, J. M., Dumas, P. Y., Vergez, F., Tavitian, S., Largeaud, L., Bidet, A., Rieu, J. B., Luquet, I., Lechevalier, N., Delabesse, E., Sarry, A., De Grande, A. C., Bérard, E., Pigneux, A., Récher, C., Simoncini, D., & Bertoli, S. (2024). Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study. *Leukemia research*, *136*, 107437. https://doi.org/10.1016/j.leukres.2024.107437

Echecopar, C., Abad, I., Galán-Gómez, V., Del Castillo, Y. M., Sisinni, L., Bueno, D., Ruz, B., & Pérez-Martínez, A. (2024). An artificial intelligence-driven predictive model for pediatric allogeneic hematopoietic stem cell transplantation using clinical variables. *European Journal of Haematology, 112*(6), 910–916. https://doi.org/10.1111/ejh.14184

Eckardt, J. N., Hahn, W., Röllig, C., Stasik, S., Platzbecker, U., Müller-Tidow, C., Serve, H., Baldus, C. D., Schliemann, C., Schäfer-Eckart, K., Hanoun, M., Kaufmann, M., Burchert, A., Thiede, C., Schetelig, J., Sedlmayr, M., Bornhäuser, M., Wolfien, M., & Middeke, J. M. (2024). Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence. *NPJ digital medicine*, *7*(1), 76. https://doi.org/10.1038/s41746-024-01076-x

El Alaoui, Y., Elomri, A., Qaraqe, M., Padmanabhan, R., Yasin Taha, R., El Omri, H., ... & Aboumarzouk, O. (2022). A review of artificial intelligence applications in hematology management: current practices and future prospects. *Journal of Medical Internet Research*, *24*(7), e36490. https://doi.org/10.2196/36490

Fan, B. E., & Chow, M. (2024). Artificial intelligence assisted diagnosis of chronic lymphocytic leukemia in a historic pediatric case using large language models. *Annals of Hematology, 103*(9), 3815-3819. https://doi.org/10.1007/s00277-024-05916-4

Fathi, E., Rezaee, M. J., Tavakkoli-Moghaddam, R., Alizadeh, A., & Montazer, A. (2020). Design of an integrated model for diagnosis and classification of pediatric acute leukemia using machine learning. *Proceedings of the Institution of Mechanical Engineers Part H Journal of Engineering in Medicine, 234*(10), 1051–1069. https://doi.org/10.1177/0954411920938567

Hoffmann, J., Eminovic, S., Wilhelm, C., Krause, S. W., Neubauer, A., Thrun, M. C., Ultsch, A., & Brendel, C. (2023). Prediction of Clinical Outcomes with Explainable Artificial Intelligence in Patients with Chronic Lymphocytic Leukemia. *Current oncology (Toronto, Ont.)*, *30*(2), 1903–1915. https://doi.org/10.3390/curroncol30020148

Hossain, M. A., Islam, A. M., Islam, S., Shatabda, S., & Ahmed, A. (2022). Symptom based explainable artificial intelligence model for leukemia detection. *IEEE Access, 10*, 57283-57298. https://doi.org/10.1109/ACCESS.2022.3176274

Husnain, A., Qayyum, M. U., Fahad, M., & Ibrar, M. (2024). Integrating AI in healthcare: advancements in petroleum fraud detection and innovations in herbal medicine for enhanced cancer treatment approaches. jurnal.itscience.org. https://doi.org/10.47709/ijmdsa.v3i4.4810

Jiaqing, X., Alivi, M. A., Mustafa, S. E., & Dharejo, N. (2023). The Impact of Social Media on Women's Body Image Perception: A Meta-Analysis of Well-being Outcomes. *International Journal of Interactive Mobile Technologies, 17*(20), 148. https://doi.org/10.3991/ijim.v17i20.44665

Jiwani, N., Gupta, K., Pau, G., & Alibakhshikenari, M. (2023). Pattern recognition of acute lymphoblastic leukemia (ALL) using computational deep learning. *IEEE Access*, *11*, 29541-29553. https://doi.org/10.1109/access.2023.3260065

Kaskovich, S., Wyatt, K. D., Oliwa, T., Graglia, L., Furner, B., Lee, J., ... & Volchenboum, S. L. (2023). Automated matching of patients to clinical trials: a patient-centric natural language processing approach for pediatric leukemia. *JCO Clinical Cancer Informatics*, *7*, e2300009. https://doi.org/10.1200/CCI.23.00009

Khan, M., Shiwlani, A., Qayyum, M. U., Sherani, A. M. K., & Hussain, H. K. (2024). Revolutionizing Healthcare with AI: Innovative Strategies in Cancer Medicine. *International Journal of Multidisciplinary Sciences and Arts*, *3*(1), 316-324. https://doi.org/10.47709/ijmdsa.v3i1.3922

Kokol, P., Završnik, J., & Blazun, H. (2017). Artificial Intelligence and Pediatrics: A Synthetic Mini Review. *Political Economy - Development: Public Service Delivery eJournal*. *2*(4), arXiv:1802.06068. https://doi.org/10.48550/arXiv.1802.06068

Mahmood, N., Shahid, S., Bakhshi, T., Riaz, S., Ghufran, H., & Yaqoob, M. (2020). Identification of significant risks in pediatric acute lymphoblastic leukemia (ALL) through machine learning (ML) approach. *Medical & Biological Engineering & Computing*, *58*, 2631-2640. https://doi.org/10.1007/s11517-020-02245-2

Mehrbakhsh, Z., Hassanzadeh, R., Behnampour, N., Tapak, L., Zarrin, Z., Khazaei, S., & Dinu, I. (2024). Machine learning-based evaluation of prognostic factors for mortality and relapse in patients with acute lymphoblastic leukemia: a comparative simulation study. *BMC Medical Informatics and Decision Making*, *24*(1), 261. https://doi.org/10.1186/s12911-024-02645-6

Mendoza-Vasquez, D., Salazar-Chavez, S., & Ugarte, W. (2021). Technological Model using Machine Learning Tools to Support Decision Making in the Diagnosis and Treatment of

Pediatric Leukemia. *Proceedings of the 17th International Conference on Web Information Systems and Technologies WEBIST, 1,* 346-353. https://doi.org/10.5220/0010684600003058

Morabito, F., Adornetto, C., Monti, P., Amaro, A., Reggiani, F., Colombo, M., Rodriguez-Aldana, Y., Tripepi, G., D'Arrigo, G., Vener, C., Torricelli, F., Rossi, T., Neri, A., Ferrarini, M., Cutrona, G., Gentile, M., & Greco, G. (2023). Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy. *Frontiers in oncology*, *13*, 1198992. https://doi.org/10.3389/fonc.2023.1198992

Pan, L., Liu, G., Lin, F., Zhong, S., Xia, H., Sun, X., & Liang, H. (2017). Machine learning applications for prediction of relapse in childhood acute lymphoblastic leukemia. *Scientific reports*, *7*(1), 7402. https://doi.org/10.1038/s41598-017-07408-0

Park, S., Park, Y. H., Huh, J., Baik, S. M., & Park, D. J. (2024). Deep learning model for differentiating acute myeloid and lymphoblastic leukemia in peripheral blood cell images via myeloblast and lymphoblast classification. *Digital Health*, *10*, 20552076241258079. https://doi.org/10.1177/20552076241258079

Ramesh, S., Chokkara, S., Shen, T., Major, A., Volchenboum, S. L., Mayampurath, A., & Applebaum, M. A. (2021). Applications of Artificial Intelligence in Pediatric Oncology: A Systematic review. *JCO Clinical Cancer Informatics, 5*, 1208–1219. https://doi.org/10.1200/cci.21.00102

Seheult, J.N., Weybright, M.J., Shi, M., Jevremovic, D., Chiu, A., Timm, M.M., Otteson, G., Olteanu, H., & Horna, P. (2024). Artificial Intelligence-Enhancement of Flow Cytometry Data Accelerates the Identification of Minimal Residual B Lymphoblastic Leukemia. *Blood*, *144*(1), 4226. https://doi.org/10.1182/blood-2024-199894

Shah, Y. A. R., Qureshi, H. A., Qureshi, S. M., Shah, S. U. R., Shiwlani, A., & Ahmad, A. (2024). A Review of Evaluating Deep Learning Techniques in Hepatic Cancer Imaging: Automated Segmentation and Tumor Quantification. *International Journal For Multidisciplinary Research 6*(5). https://doi.org/10.36948/ijfmr.2024.v06i05.26719

Shiwlani, A., Khan, M., Sherani, A. M. K., Qayyum, M. U., & Hussain, H. K. (2024). REVOLUTIONIZING HEALTHCARE: THE IMPACT OF ARTIFICIAL INTELLIGENCE ON PATIENT CARE, DIAGNOSIS, AND TREATMENT. *JURIHUM: Jurnal Inovasi dan Humaniora*, *1*(5), 779-790.

Shiwlani, A., Kumar, S., Hasan, S. U., Kumar, S., & Naguib, J. S. (2024). Advancing Hepatology with AI: A Systematic Review of Early Detection Models for Hepatitis-Associated Liver Cancer. *International Journal of Innovative Science and Research Technology (IJISRT), 9*(11), 2522-2536. https://doi.org/10.5281/zenodo.14546062

Sisk, B. A., Antes, A. L., & DuBois, J. M. (2024). An Overarching Framework for the Ethics of Artificial Intelligence in Pediatrics. *JAMA Pediatrics,* 178(3), 213-214. https://doi.org/10.1001/jamapediatrics.2023.5761

Sumathi, G., Kumar, V., Murali, G., & Sakthi, R. (2024, August). Advanced Machine Learning Techniques for Accurate Detection and Diagnosis of Acute Lymphoblastic Leukemia (ALL). *2024 5th International Conference on Electronics and Sustainable Communication Systems (ICESC),* 1362-1366, https://doi.org/10.1109/icesc60852.2024.10689891

Suzuki, K., Watanabe, N., Torii, S., Inano, T., Kinoshita, S., Yamada, K., ... & Takaku, T. (2024). BCR:: ABL1-Induced Mitochondrial Morphological Changes As a Novel Biomarker for

the Artificial Intelligence-Driven Flow Cytometric Detection of Chronic Myeloid Leukemia Cells. *Blood, 144*, 6566. https://doi.org/10.1182/blood-2024-199940

Tian, Z., Sheng, Y., Han, F., Yu, L., Deng, Z., Jiang, Y., & Peng, H. (2024). The Role of Artificial Intelligence in Differential Diagnosis and Prognostic Significance of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *Blood, 144*(1), 6326-6326. https://doi.org/10.1182/blood-2024-201479

Uysal, I., & Kose, U. (2023). Development of a Simulation Environment for the Importance of Histone Deacetylase in Childhood Acute Leukemia with Explainable Artificial Intelligence. *BRAIN. Broad Research in Artificial Intelligence and Neuroscience*, *14*(3), 254-286. https://doi.org/10.18662/brain/14.3/474

Varol Malkoçoğlu, A. B., & İşeri, İ. (2024). CLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA CELLS USING ARTIFICIAL INTELLIGENCE. *Mühendislik Bilimleri Ve Tasarım Dergisi, 12*(3), 488-504. https://doi.org/10.21923/jesd.1466823

Yang, Y., Zhang, Y., & Li, Y. (2023). Artificial intelligence applications in pediatric oncology diagnosis. *Exploration of targeted anti-tumor therapy*, *4*(1), 157–169. https://doi.org/10.37349/etat.2023.00127

Zhou, M., Wu, K., Yu, L., Xu, M., Yang, J., Shen, Q., Liu, B., Shi, L., Wu, S., Dong, B., Wang, H., Yuan, J., Shen, S., & Zhao, L. (2021). Development and Evaluation of a Leukemia Diagnosis System Using Deep Learning in Real Clinical Scenarios. *Frontiers in Pediatrics, 9*, 693676. https://doi.org/10.3389/fped.2021.693676